Aditxt, Inc. (ADTX) Stock Price & Analysis
Aditxt, Inc. (ADTX) closed at USD 0 on Friday, October 23, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0; the Oct 23, 2026 session ranged USD 0–0 on volume of 9,762,594 shares. Market capitalization is —, with a 52-week range of USD 0–5,833.51 (PNK). Source: Nexqual, retrieved October 24, 2026 at 12:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ADTX.md
Key facts (ADTX)
- Last four reported quarters (through Mar 31, 2026): revenue $14K, net income -$53.3M (-372062.4% margin) (SEC filings).
- Total return with dividends: 1Y -100.0% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ADTX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $105K | $934K | $645K | $134K | $3K | $14K |
| Gross profit | $27K | $167K | -$112K | -$493K | $0K | — |
| Operating income | -$41.9M | -$25.5M | -$26.1M | -$27.9M | -$19.6M | -$18.3M |
| Net income | -$46.4M | -$27.6M | -$32.7M | -$40.4M | -$43.1M | -$53.3M |
| EPS (diluted) | -$1183104576000.00 | -$145374048000.00 | -$659949850.08 | -$597980210.94 | -$31153.41 | — |
| Free cash flow | — | -$22.8M | -$19.2M | — | -$25.7M | — |
| Gross margin | 25.8% | 17.9% | -17.3% | -368.3% | 8.4% | — |
| Operating margin | -39925.1% | -2728.9% | -4039.6% | -20796.1% | -612542.2% | -127821.4% |
| Net margin | -44148.9% | -2961.3% | -5068.5% | -30117.9% | -1349028.2% | -372062.4% |
| Revenue growth | — | +789.0% | -30.9% | -79.2% | -97.6% | — |
| Cash + short-term investments | — | $2.8M | $97K | $833K | $3.2M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Mar 31, 2026) (ADTX)
Total return (dividends reinvested) (ADTX)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -100.0% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -100.0% | -99.9% |
| Volatility (annualized) | 416.4% | 238.2% |
| Max drawdown | -100.0% (Oct 2025→Oct 2026) | -100.0% (Nov 2021→Oct 2026) |
ADTX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2023) | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2023) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 12:39 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 5,833.51 |
| Volume | 9,762,594 shares |
| Market Cap | — |
| Exchange | PNK |
Technical Analysis (ADTX)
Nexqual's technical model rates ADTX "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 12:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 20.17 (oversold) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Earnings (ADTX)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -10,534.33 vs est -1,723.68 ▼ miss |
| 2023-03-31 | USD -282.96 vs est -190.08 ▼ miss |
| 2022-12-31 | USD 673.92 vs est -319.68 ▲ beat |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Financials & Fundamentals (ADTX)
| Total Revenue | $14,336 |
|---|---|
| Revenue Growth (latest quarter, YoY) | +1094.40% |
| Gross Margin | +19.89% |
| Operating Margin | -35873.53% |
| Profit Margin | +0.00% |
| Current Ratio | 0.06 |
| Total Cash | $268,852 |
| Total Debt | $4.23M |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Ownership (ADTX)
| Insider Ownership | +0.41% |
|---|---|
| Institutional Ownership | +0.46% |
| Shares Outstanding | 997.98M |
| Float | 815,399 |
| Short % of Float | +34.50% |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 12:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt